Banner

Conjugated Monoclonal Antibodies Global Market Report 2023 – By Drugs (Adcetris, Kadcyla), By Technology (Cleavable Linker, Non-cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Other Applications) – Market Size, Trends, And Market Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | SKU CODE : h1161 | Delivery Time: 2-3 business days | Format :


Conjugated monoclonal antibodies refer to a compound formed from a monoclonal antibody that has been chemically coupled to a medication. The monoclonal antibody binds to particular proteins or receptors that are present on particular cell types, such as cancer cells. The associated medicine enters these cells, kills them, and leaves the rest of the cells alone.

The main types of drugs in conjugated monoclonal antibodies are advertised and kadcyla. Adcetris is a brand-name pharmaceutical drug intended to cure adults with certain types of lymphoma. Lymphoma is a cancer that attacks the lymphatic system and lymphocytes, which are white blood cells. The different technologies include cleavable linkers and non-cleavable linkers and are used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and others.

The conjugated monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. The conjugated monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The global conjugated monoclonal antibodies market grew from $9.64 billion in 2022 to $10.3 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The conjugated monoclonal antibodies market is expected to grow from $12.86 billion in 2027 at a CAGR of 5.7%.

The increasing popularity and therapeutic potential of conjugated monoclonal antibodies, especially antibody-drug conjugates, is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs), a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumour cells, are predominantly used in the treatment of cancer. In the last three to four years, the U.S. Food and Drug Administration has approved only three antibody-drug conjugates, indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies, mainly in the field of cancer, which in turn aids in the growth of the market.

The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the first FDA-approved radioimmunotherapy drug, Yttrium 90 Ibritumomab Tiuxetan Therapeutic (Zevalin), is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas that was approved in December 2019, costs between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for the patients and healthcare systems of underdeveloped countries, which hinders the growth of the conjugated monoclonal antibody market.

Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies and shaping the market. For instance, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar’s MNPR-101, a humanised urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage, to a therapeutic radioisotope of NorthStar to create a highly selective agent, that has the potential to kill aberrantly activated cytokine-producing immune cells.

AstraZeneca, a UK-based pharmaceutical company, announced a $6 billion partnership with Daiichi Sankyo in July 2020.This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC), which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumour cells. Daiichi Sankyo is a Japanese-based pharmaceutical company engaged in the development of antibody-drug conjugates.

Major players in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche, Bristol-Myers Squibb, and Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc.

North America was the largest region in the conjugated monoclonal antibody market in 2022. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market during the forecast period. The regions covered in the global conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The global conjugated monoclonal antibodies market is segmented -

1) By Drugs: Adcetris, Kadcyla

2) By Technology: Cleavable Linker, Non-cleavable Linker

3) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Other Applications

    Table Of Contents

    1. Executive Summary

    2. Conjugated Monoclonal Antibodies Market Characteristics

    3. Conjugated Monoclonal Antibodies Market Trends And Strategies

    4. Conjugated Monoclonal Antibodies Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Conjugated Monoclonal Antibodies Market

    4.2 Ukraine-Russia War Impact On Conjugated Monoclonal Antibodies Market

    4.3 Impact Of High Inflation On Conjugated Monoclonal Antibodies Market

    5. Conjugated Monoclonal Antibodies Market Size And Growth

    5.1. Global Conjugated Monoclonal Antibodies Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Conjugated Monoclonal Antibodies Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Conjugated Monoclonal Antibodies Market Segmentation

    6.1. Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Adcetris

    Kadcyla

    6.2. Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Cleavable Linker

    Non-cleavable Linker

    6.3. Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Blood Cancer

    Breast Cancer

    Ovarian Cancer

    Lung Cancer

    Brain Tumour

    Other Applications

    7. Conjugated Monoclonal Antibodies Market Regional And Country Analysis

    7.1. Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Conjugated Monoclonal Antibodies Market

    8.1. Asia-Pacific Conjugated Monoclonal Antibodies Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Conjugated Monoclonal Antibodies Market

    9.1. China Conjugated Monoclonal Antibodies Market Overview

    9.2. China Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Conjugated Monoclonal Antibodies Market

    10.1. India Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Conjugated Monoclonal Antibodies Market

    11.1. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Conjugated Monoclonal Antibodies Market

    12.1. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Conjugated Monoclonal Antibodies Market

    13.1. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Conjugated Monoclonal Antibodies Market

    14.1. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Conjugated Monoclonal Antibodies Market

    15.1. Western Europe Conjugated Monoclonal Antibodies Market Overview

    15.2. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Conjugated Monoclonal Antibodies Market

    16.1. UK Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Conjugated Monoclonal Antibodies Market

    17.1. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Conjugated Monoclonal Antibodies Market

    18.4. France Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Conjugated Monoclonal Antibodies Market

    19.1. Eastern Europe Conjugated Monoclonal Antibodies Market Overview

    19.2. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Conjugated Monoclonal Antibodies Market

    20.1. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Conjugated Monoclonal Antibodies Market

    21.1. North America Conjugated Monoclonal Antibodies Market Overview

    21.2. North America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Conjugated Monoclonal Antibodies Market

    22.1. USA Conjugated Monoclonal Antibodies Market Overview

    22.2. USA Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Conjugated Monoclonal Antibodies Market

    23.1. South America Conjugated Monoclonal Antibodies Market Overview

    23.2. South America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Conjugated Monoclonal Antibodies Market

    24.1. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Conjugated Monoclonal Antibodies Market

    25.1. Middle East Conjugated Monoclonal Antibodies Market Overview

    25.2. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Conjugated Monoclonal Antibodies Market

    26.1. Africa Conjugated Monoclonal Antibodies Market Overview

    26.2. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Conjugated Monoclonal Antibodies Market Competitive Landscape And Company Profiles

    27.1. Conjugated Monoclonal Antibodies Market Competitive Landscape

    27.2. Conjugated Monoclonal Antibodies Market Company Profiles

    27.2.1. Pfizer Inc.

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. F. Hoffmann-LA

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Bristol -Myers Squibb

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Merck & Co. Inc.

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Immunomedics Inc.

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Conjugated Monoclonal Antibodies Pipeline Analysis

    29. Key Mergers And Acquisitions In The Conjugated Monoclonal Antibodies Market

    30. Conjugated Monoclonal Antibodies Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Pfizer Inc. Financial Performance
  • Table 47: F. Hoffmann-LA Financial Performance
  • Table 48: Bristol -Myers Squibb Financial Performance
  • Table 49: Merck & Co. Inc. Financial Performance
  • Table 50: Immunomedics Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Pfizer Inc. Financial Performance
  • Figure 47: F. Hoffmann-LA Financial Performance
  • Figure 48: Bristol -Myers Squibb Financial Performance
  • Figure 49: Merck & Co. Inc. Financial Performance
  • Figure 50: Immunomedics Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report